ArticleCancer immunology, immunotherapy : CII2019

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.

Amit Mahipal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.